Cantel Medical Corp. (CMD) Given Average Recommendation of “Buy” by Brokerages
Cantel Medical Corp. (NYSE:CMD) has been assigned an average broker rating score of 2.00 (Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold recommendation and two have issued a strong buy recommendation on the company. Cantel Medical Corp.’s rating score has improved by 14.2% in the last 90 days as a result of a number of analysts’ ratings changes.
Analysts have set a 12 month consensus price objective of $100.00 for the company and are anticipating that the company will post $0.52 EPS for the current quarter, according to Zacks. Zacks has also given Cantel Medical Corp. an industry rank of 88 out of 265 based on the ratings given to its competitors.
A number of brokerages have recently weighed in on CMD. Needham & Company LLC restated a “hold” rating on shares of Cantel Medical Corp. in a research report on Friday, September 1st. Zacks Investment Research upgraded Cantel Medical Corp. from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Sidoti upgraded Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 price target for the company in a research report on Wednesday, August 2nd. Finally, Benchmark Co. cut Cantel Medical Corp. from a “buy” rating to a “hold” rating in a research report on Friday, June 9th.
Cantel Medical Corp. (NYSE CMD) traded up 0.18% during midday trading on Friday, hitting $85.32. 59,353 shares of the stock were exchanged. The firm has a 50-day moving average price of $77.92 and a 200-day moving average price of $76.68. The stock has a market cap of $3.54 billion, a P/E ratio of 50.49 and a beta of 1.23. Cantel Medical Corp. has a one year low of $68.19 and a one year high of $88.81.
In related news, Chairman Charles M. Diker sold 35,000 shares of Cantel Medical Corp. stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $75.52, for a total transaction of $2,643,200.00. Following the completion of the sale, the chairman now owns 3,114,520 shares in the company, valued at approximately $235,208,550.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 14.90% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. Navellier & Associates Inc purchased a new stake in Cantel Medical Corp. during the 2nd quarter worth about $275,000. Kimelman & Baird LLC purchased a new stake in Cantel Medical Corp. during the 2nd quarter worth about $17,459,000. Ashford Capital Management Inc. purchased a new stake in Cantel Medical Corp. during the 2nd quarter worth about $347,000. Koch Industries Inc. purchased a new stake in Cantel Medical Corp. during the 2nd quarter worth about $407,000. Finally, 1st Global Advisors Inc. purchased a new stake in Cantel Medical Corp. during the 2nd quarter worth about $593,000. Hedge funds and other institutional investors own 83.79% of the company’s stock.
Cantel Medical Corp. Company Profile
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.